B Sautois

Summary

Country: Belgium

Publications

  1. ncbi request reprint [New treatments for castration-resistant prostate cancer]
    B Sautois
    Service d Oncologie Medicale, CHU de Liege, Belgique
    Rev Med Liege 68:94-6. 2013
  2. ncbi request reprint [Everolimus (RAD001/Afinitor) in the treatment of metastatic cell carcinoma]
    C Gennigens
    Service d Oncologie Medicale, CHU de Liege, Belgique
    Rev Med Liege 65:212-6. 2010
  3. ncbi request reprint [Radiation recall dermatitis after oral cyclophosphamide]
    C Mievis
    Service de Radiotherapie, CHU de Liege, Belgique
    Rev Med Liege 64:179-81. 2009

Collaborators

Detail Information

Publications3

  1. ncbi request reprint [New treatments for castration-resistant prostate cancer]
    B Sautois
    Service d Oncologie Medicale, CHU de Liege, Belgique
    Rev Med Liege 68:94-6. 2013
    ..Although still modest these results were deemed clinically significant and led to the reimbursement of Jevtana (cabazitaxel) and Zytiga (abiraterone) in Belgium in 2012...
  2. ncbi request reprint [Everolimus (RAD001/Afinitor) in the treatment of metastatic cell carcinoma]
    C Gennigens
    Service d Oncologie Medicale, CHU de Liege, Belgique
    Rev Med Liege 65:212-6. 2010
    ..Everolimus (Afinitor), a mTOR ("mammalian Target Of Rapamycin") inhibitor, has just been validated and reimbursed in this setting. In this paper, we will review the mechanism of action and the clinical results of everolimus...
  3. ncbi request reprint [Radiation recall dermatitis after oral cyclophosphamide]
    C Mievis
    Service de Radiotherapie, CHU de Liege, Belgique
    Rev Med Liege 64:179-81. 2009
    ..Spontaneous resolution was observed within 6 weeks after discontinuation of cyclophosphamide and with local supportive care. To our knowledge this is the first reported case of radiation recall dermatitis after oral cyclophosphamide...